Sign up
Pharma Capital

Imugene well-funded to progress clinical milestones

The company is currently fully funded in supporting all clinical research programs.
australian bank notes
The company’s vaccines are targeting the gastric and lung cancer market

Imugene Ltd (ASX:IMU) finished the March quarter with $21 million in the bank, positioning it well as it progresses its commercial and clinical milestones over the coming quarters.

The company has a strong pipeline of cancer vaccines in development.

In March 2019, the company dosed its first patient with its HER-Vaxx (IMU131) cancer vaccine for the treatment of HER-2 positive gastric cancer patients.

This marked an important milestone for the company in advancing its Phase II trials.

Additionally, Imugene presented the Phase 1b study results of its HER-Vaxx cancer vaccine at the American Association for Cancer Research (AACR) meeting in April 2019.

READ: Imugene presents positive new data validating its human cancer vaccine KEY-Vaxx

Furthermore, positive new data findings from the active immunisation studies for KEY-Vaxx earlier this year provided proof of concept and validation for the human PD-1 cancer vaccine.

The FDA meeting in February 2019 was productive and provided Imugene with a clear roadmap for a successful IND submission and subsequent clinical development of KEY-Vaxx.

READ: Imugene gets development roadmap for cancer vaccine from FDA meeting

View full IMU profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.